• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺炎链球菌临床分离株对司帕沙星的耐药性:gyrA和parC基因中多个突变的作用

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.

作者信息

Taba H, Kusano N

机构信息

First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.

出版信息

Antimicrob Agents Chemother. 1998 Sep;42(9):2193-6. doi: 10.1128/AAC.42.9.2193.

DOI:10.1128/AAC.42.9.2193
PMID:9736534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC105774/
Abstract

Antimicrobial susceptibility testing revealed among 150 clinical isolates of Streptococcus pneumoniae 4 pneumococcal isolates with resistance to fluoroquinolones (MIC of ciprofloxacin, >/=32 microgram/ml; MIC of sparfloxacin, >/=16 microgram/ml). Gene amplification and sequencing analysis of gyrA and parC revealed nucleotide changes leading to amino acid substitutions in both GyrA and ParC of all four fluoroquinolone-resistant isolates. In the case of strains 182 and 674 for which sparfloxacin MICs were 16 and 64 microgram/ml, respectively, nucleotide changes were detected at codon 81 in gyrA and codon 79 in parC; these changes led to an Ser-->Phe substitution in GyrA and an Ser-->Phe substitution in ParC. Strains 354 and 252, for which sparfloxacin MICs were 128 microgram/ml, revealed multiple mutations in both gyrA and parC. These strains exhibited nucleotide changes at codon 85 leading to a Glu-->Lys substitution in GyrA, in addition to Ser-79-->Tyr and Lys-137-->Asn substitutions in ParC. Moreover, strain 252 showed additional nucleotide changes at codon 93, which led to a Trp-->Arg substitution in GyrA. These results suggest that sparfloxacin resistance could be due to the multiple mutations in GyrA and ParC. However, it is possible that other yet unidentified mutations may also be involved in the high-level resistance to fluoroquinolones in S. pneumoniae.

摘要

对150株肺炎链球菌临床分离株进行的药敏试验显示,有4株肺炎球菌分离株对氟喹诺酮类耐药(环丙沙星的MIC≥32微克/毫升;司帕沙星的MIC≥16微克/毫升)。对gyrA和parC进行基因扩增和测序分析发现,所有4株氟喹诺酮耐药分离株的GyrA和ParC中均有导致氨基酸替代的核苷酸变化。对于司帕沙星MIC分别为16和64微克/毫升的182和674菌株,在gyrA的第81密码子和parC的第79密码子检测到核苷酸变化;这些变化导致GyrA中Ser→Phe替代和ParC中Ser→Phe替代。司帕沙星MIC为128微克/毫升的354和252菌株在gyrA和parC中均显示多个突变。这些菌株在第85密码子处出现核苷酸变化,导致GyrA中Glu→Lys替代,此外ParC中Ser-79→Tyr和Lys-137→Asn替代。此外,252菌株在第93密码子处还显示额外的核苷酸变化,导致GyrA中Trp→Arg替代。这些结果表明,司帕沙星耐药可能是由于GyrA和ParC中的多个突变。然而,其他尚未鉴定的突变也可能参与肺炎链球菌对氟喹诺酮类的高水平耐药。

相似文献

1
Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.肺炎链球菌临床分离株对司帕沙星的耐药性:gyrA和parC基因中多个突变的作用
Antimicrob Agents Chemother. 1998 Sep;42(9):2193-6. doi: 10.1128/AAC.42.9.2193.
2
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.新型氟喹诺酮类药物对肺炎链球菌临床分离株的活性,包括那些gyrA、parC和parE基因座发生突变的分离株。
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
3
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.DNA 回旋酶和拓扑异构酶IV是环丙沙星作用于肺炎链球菌的双重靶点。
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
4
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.gyrA和parC基因突变对体内外获得的肺炎链球菌突变体氟喹诺酮耐药性的影响。
Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
5
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.阴沟肠杆菌喹诺酮耐药临床分离株中gyrA和parC基因突变的检测
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
6
Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.香港耐氟喹诺酮沙门氏菌拓扑异构酶基因的突变
Antimicrob Agents Chemother. 2003 Nov;47(11):3567-73. doi: 10.1128/AAC.47.11.3567-3573.2003.
7
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用:喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
8
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.自1994 - 1995年以来美国肺炎链球菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 2002 Mar;46(3):680-8. doi: 10.1128/AAC.46.3.680-688.2002.
9
Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.耐氟喹诺酮口腔链球菌分离株与实验室衍生突变株中gyrA和parC基因突变及耐药水平的比较。
J Antimicrob Chemother. 2000 Jun;45(6):771-5. doi: 10.1093/jac/45.6.771.
10
Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.吉米沙星强大的抗肺炎球菌活性与对回旋酶和拓扑异构酶IV的双重靶向作用、在体内对回旋酶的靶点偏好以及在体外增强可裂解复合物的稳定性有关。
Antimicrob Agents Chemother. 2000 Nov;44(11):3112-7. doi: 10.1128/AAC.44.11.3112-3117.2000.

引用本文的文献

1
N-Acylated Ciprofloxacin Derivatives: Synthesis and In Vitro Biological Evaluation as Antibacterial and Anticancer Agents.N-酰化环丙沙星衍生物:作为抗菌和抗癌药物的合成及体外生物学评价
ACS Omega. 2023 May 18;8(21):18663-18684. doi: 10.1021/acsomega.3c00554. eCollection 2023 May 30.
2
Fluoroquinolones and BK Virus Nephropathy: A Myth or a Reality.氟喹诺酮类药物与BK病毒肾病:神话还是现实。
Indian J Nephrol. 2018 Jul-Aug;28(4):257-264. doi: 10.4103/ijn.IJN_251_17.
3
JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.日本传染病学会/日本化疗学会《呼吸道传染病治疗指南》:日本传染病学会/日本化疗学会传染病临床管理指南/指南编写委员会呼吸道传染病工作组
J Infect Chemother. 2016 Jul;22(7 Suppl):S1-S65. doi: 10.1016/j.jiac.2015.12.019. Epub 2016 Jun 15.
4
Draft Genome Sequence of Extensively Drug-Resistant Acinetobacter baumannii Strain CUAB1 from a Patient in Hong Kong, China.来自中国香港一名患者的广泛耐药鲍曼不动杆菌菌株CUAB1的基因组序列草图
Genome Announc. 2015 May 14;3(3):e00442-15. doi: 10.1128/genomeA.00442-15.
5
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.肺炎链球菌对氟喹诺酮类药物的耐药性:浓度-时间曲线下面积与最低抑菌浓度比值以及加替沙星、吉米沙星、左氧氟沙星和莫西沙星导致的耐药性发展情况
Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20. doi: 10.1128/AAC.00646-06. Epub 2007 Feb 12.
6
DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.解脲脲原体和人型支原体临床分离株中对氟喹诺酮类耐药的DNA促旋酶和拓扑异构酶IV突变
Antimicrob Agents Chemother. 2003 Oct;47(10):3323-5. doi: 10.1128/AAC.47.10.3323-3325.2003.
7
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.在体外药效学模型中,突变预防浓度靶向的莫西沙星和左氧氟沙星对肺炎链球菌的活性。
Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003.
8
Longitudinal assessment of antipneumococcal susceptibility in the United States.美国抗肺炎球菌药敏性的纵向评估。
Antimicrob Agents Chemother. 2002 Aug;46(8):2651-5. doi: 10.1128/AAC.46.8.2651-2655.2002.
9
In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.新型非氟化喹诺酮类药物PGE 9262932和PGE 9509924对具有DNA旋转酶和拓扑异构酶IV特定突变的金黄色葡萄球菌和肺炎链球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2002 Jun;46(6):1651-7. doi: 10.1128/AAC.46.6.1651-1657.2002.
10
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述:聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.

本文引用的文献

1
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.主动外排作为肺炎链球菌对环丙沙星耐药的一种机制。
Antimicrob Agents Chemother. 1997 Sep;41(9):1973-8. doi: 10.1128/AAC.41.9.1973.
2
Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.肺炎链球菌中赋予氟喹诺酮耐药性的parE基因突变特征分析。
Antimicrob Agents Chemother. 1997 May;41(5):1166-7. doi: 10.1128/AAC.41.5.1166.
3
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.肺炎链球菌对高水平氟喹诺酮类药物耐药需要parC和gyrA发生突变。
Antimicrob Agents Chemother. 1996 Dec;40(12):2760-4. doi: 10.1128/AAC.40.12.2760.
4
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用:喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
5
Antibiotic resistance in Streptococcus pneumoniae.肺炎链球菌中的抗生素耐药性。
Clin Infect Dis. 1997 Jan;24 Suppl 1:S85-8. doi: 10.1093/clinids/24.supplement_1.s85.
6
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.gyrA和parC基因突变对体内外获得的肺炎链球菌突变体氟喹诺酮耐药性的影响。
Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
7
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.拓扑异构酶IV和DNA促旋酶作为环丙沙星在肺炎链球菌中的作用靶点。
Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321.
8
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.肺炎链球菌DNA拓扑异构酶IV的ParC亚基是氟喹诺酮类药物的主要作用靶点,并与DNA回旋酶A亚基协同形成耐药表型。
Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.
9
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析:在氟喹诺酮耐药性中的作用
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
10
In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.司帕沙星与现有抗微生物药物对呼吸道病原体的体外活性比较。
J Antimicrob Chemother. 1996 May;37 Suppl A:1-18. doi: 10.1093/jac/37.suppl_a.1.